Infliximab
Mandatory switching policies increased etanercept, infliximab biosimilar use in Canada
Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.
VIDEO: How COVID-19 has impacted ulcerative colitis care
In this Healio video, Marla Dubinsky, MD, chief of pediatric gastroenterology at Mount Sinai Kravis Children’s Hospital, discusses recent COVID-19 has impacted ulcerative colitis care.
Celltrion submits application for subcutaneous infliximab in inflammatory bowel disease
Celltrion has submitted a biologics license application to the FDA for the consideration of a subcutaneous formulation of infliximab in the treatment of inflammatory bowel disease, according to a press release.
‘Proactive education’ critical to preparing patients for likely biosimilar switch
DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can help reduce anxiety and bias if/when their insurance opts to switch, according to a presenter at the Crohn’s and Colitis Congress.
Treatment retention ‘high’ after infliximab biosimilar-to-biosimilar switch
PHILADELPHIA — Patients who switched from one infliximab biosimilar to another experienced comparable treatment retention rates, according to data presented at ACR Convergence 2022.
Top in GI: Infliximab retreatment; short bowel syndrome guidance
After 26 weeks of retreatment with infliximab, 35% of patients with Crohn’s disease achieved remission, according to recent data.
Infliximab retreatment results in remission in 35% of patients with Crohn’s disease
After previously discontinuing infliximab, 35% of patients with Crohn’s disease achieved remission at 26 weeks with drug retreatment, according to a study published in The American Journal of Gastroenterology.
Third COVID vaccine provides ‘significant boost’ in antibody response in patients with IBD
Immunosuppressed patients with inflammatory bowel disease who received a third COVID-19 vaccine demonstrated improved antibody binding, although the response was reduced in patients receiving infliximab and tofacitinib.
Biosimilar-to-biosimilar switching safe, effective in rheumatology
Although biosimilar-to-biosimilar switching is not covered by health regulations or guidance, a systematic literature review suggests the practice is safe and effective, according to data published in BioDrugs.
IBD patients should ‘not delay their infusion’ if stable with COVID-19 infection
Use of biologics did not worsen stable SARS-CoV-2 infection in patients with inflammatory bowel disease if given within 2 weeks of virus detection, according to research published in Clinical Gastroenterology and Hepatology.